<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Perm Medical Journal</journal-id><journal-title-group><journal-title xml:lang="en">Perm Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Пермский медицинский журнал (сетевое издание "Perm medical journal")</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0136-1449</issn><issn publication-format="electronic">2687-1408</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">112476</article-id><article-id pub-id-type="doi">10.17816/pmj39548-57</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original studies</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Hormone-inactive adrenal tumors in clinician’s practice</article-title><trans-title-group xml:lang="ru"><trans-title>Гормонально-неактивные образования надпочечников в практике врача-клинициста</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0417-8941</contrib-id><contrib-id contrib-id-type="spin">2299-4784</contrib-id><name-alternatives><name xml:lang="en"><surname>Chzhen</surname><given-names>T. R.</given-names></name><name xml:lang="ru"><surname>Чжен</surname><given-names>Т. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assistant, Department of Faculty Therapy, Endocrinology, Allergology and Immunology</p></bio><bio xml:lang="ru"><p>ассистент кафедры факультетской терапии, эндокринологии, аллергологии и иммунологии</p></bio><email>doctortrtr@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0425-6567</contrib-id><contrib-id contrib-id-type="spin">3072-5384</contrib-id><name-alternatives><name xml:lang="en"><surname>Kiseleva</surname><given-names>T. P.</given-names></name><name xml:lang="ru"><surname>Киселева</surname><given-names>Т. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor of the Department of Faculty Therapy, Endocrinology, Allergology and Immunology</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор кафедры факультетской терапии, эндокринологии, аллергологии и иммунологии</p></bio><email>doctortrtr@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Ural State Medical University</institution></aff><aff><institution xml:lang="ru">Уральский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">City Clinical Hospital № 40</institution></aff><aff><institution xml:lang="ru">Городская клиническая больница № 40</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-11-10" publication-format="electronic"><day>10</day><month>11</month><year>2022</year></pub-date><volume>39</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>48</fpage><lpage>57</lpage><history><date date-type="received" iso-8601-date="2022-11-09"><day>09</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-11-09"><day>09</day><month>11</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Эко-Вектор</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://permmedjournal.ru/PMJ/article/view/112476">https://permmedjournal.ru/PMJ/article/view/112476</self-uri><abstract xml:lang="en"><p><bold>Objective.</bold> To study the clinical picture, malignancy potential of hormone-inactive adrenal tumors (HIAT) by the results of computed tomography (CT) to identify the most significant clinical and diagnostic signs.</p> <p><bold>Materials and methods.</bold> Case histories of 65 patients operated for HIAT (group 1) and 52 ambulatory records of HIAT patients (group 2) observed in the polyclinic were retrospectively studied. All patients underwent survey, antropometry, biochemical blood analysis, adrenal hormone level, CT of adrenal glands.</p> <p><bold>Results.</bold> The operated patients in 81.6 % of cases were under sixty, nonoperated – in 73 % of cases over sixty. The size of tumor in patients of group 1 in 84.7 % exceeded 4 cm, in group 2 – in 98.1 % was less than 4 cm. HIAT size, CT-density in NF were significantly lower (<italic>р</italic> = 0,000 and <italic>р</italic> = 0,000, respectively), but the level of morning cortisol, observation period and age were significantly higher in the group of nonoperated patients. (<italic>р</italic> = 0,013, <italic>р</italic> = 0,000 and <italic>р</italic> = 0,000, respectively). According to the results of comparative analysis of the clinical manifestations of the autonomous cortisol secretion (arterial hypertension, obesity) in the groups of nonoperated and operated patients with HIAT, statistically significant differences were established (<italic>р</italic> = 0,000, <italic>р</italic> = 0,002 respectively). In group 1, stage 2 AH was diagnosed more often and obesity – rarely. No statistically significant differences were detected in the analysis of carbohydrate metabolism disorders, osteoporosis, dyslipidemia (<italic>р</italic> = 0,531, р <italic>р</italic> = 0,322, <italic>р</italic> = 0,105). Correlation analysis of HIAT size with the period of dynamic observation and CT-density in NF showed a negative notable (<italic>р</italic> = -0,606, <italic>р</italic> = 0,000) and a positive moderate (<italic>р</italic> = 0,391, <italic>р</italic> = 0,036) (respectively) tightness of links by Chaddock scale. In case of a 1 cm increase in HIAT size, CT-density in NF is expected to rise by 1,857 HU.</p> <p><bold>Conclusions.</bold> 1. To determine the indications to adrenalectomy, it is necessary to take into account the size and native density of the adrenal tumor by the results of computed tomography as well as clinical and laboratory data. With the values of HIAT size ≥ 4.0 cm in combination with CT-density in NF ≥ 12 HU, adrenalectomy is recommended. 2. In case of a 1 cm increase in HIAT size, rise in CT-density by 1,857 HU is expected. It is worthwhile to control CT-phenotype of HIAT in nonoperated ambulatory patients to determine the malignancy potential of HIAT and up-to-date surgical treatment.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Изучить клиническую картину, потенциал злокачественности гормонально-неактивных образований надпочечников (ГНОН) по КТ, сопоставить с описанием их гистологического заключения для определения наиболее значимых клинико-диагностических признаков ГНОН.</p> <p><bold>Материалы и методы.</bold> Ретроспективно изучены истории болезни 65 прооперированных пациентов с ГНОН, находившихся на стационарном лечении в хирургическом отделении и 52 амбулаторных карт неоперированных пациентов с ГНОН, наблюдающихся в поликлинике многопрофильной больницы г. Екатеринбурга Свердловской области. Всем пациентам проводили: анкетирование, антропометрию, биохимическое исследование крови, исследование уровня надпочечниковых гормонов, КТ надпочечников, фиброгастродуоденоскопию.</p> <p><bold>Результаты.</bold> Женщин – 47 (72,3 %) и 44 (84,6 %), что значимо больше по сравнению с мужчинами – 18 (27,7 %) и 8 (15,4 %), одинаковая частота локализации ГНОН в правом – 26 (40 %) и левом – 28 (43,1 %) надпочечнике в группе оперированных, локализация ГНОН в левом надпочечнике – 25 (48,1 %) – выше по сравнению с правым надпочечником – 14 (26,9 %) – в группе неоперированных.</p> <p>Размер ГНОН по КТ 5,4 [4,6–7,6] см против 1,95 [1,3–2,4] см, <italic>р </italic>&lt; 0,001, КТ-плотность в нативную фазу (НФ) 14 [8–27] единиц Хаунсфилда (HU) против 4 [–13,5–10,5] HU, <italic>р </italic>&lt; 0,001, в группе оперированных были значимо выше по сравнению с группой неоперированных. Уровень утреннего кортизола 442 [290–588] нмоль/л против 285 [181–450] нмоль/л, <italic>р</italic> = 0,013, возраст пациентов – 68,5 [60–71] г. против 47 [35–58] лет, <italic>р </italic>&lt; 0,001, период наблюдения – 85 [43–113,25] месяцев против 10 [6–28] месяцев, <italic>р </italic>&lt; 0,001, в группе неоперированных.</p> <p>Корреляционный анализ показал слабую по шкале Чеддока связь между размером ГНОН и КТ-плотностью в нативную фазу. При увеличении размера ГНОН на 1 см следует ожидать увеличение КТ-плотности ГНОН на 1,857 HU (<italic>р</italic> = 0,036). По результатам сравнительного анализа клинических проявлений автономной секреции кортизола: артериальной гипертензии, ожирения в группах неоперированных и оперированных пациентов с ГНОН были установлены статистически значимые различия (<italic>p </italic>&lt; 0,001, <italic>p</italic> = 0,002 соответственно).</p> <p><bold>Выводы. </bold>Для определения показаний к адреналэктомии следует учитывать размер ГНОН в сочетании с КТ-плотностью в НФ. При увеличении размера ГНОН на 1 см следует ожидать увеличение КТ-плотности в НФ на 1,857 HU. Целесообразно контролировать КТ-фенотип ГНОН у неоперированных амбулаторных пациентов для определения потенциала злокачественности ГНОН и своевременного хирургического лечения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>adrenal incidentaloma</kwd><kwd>hormonal-inactive adrenal tumors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>инциденталома надпочечника</kwd><kwd>гормонально-неактивные образования надпочечников</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Nieman L.K., Biller B.M., Findling J.W. et al. Treatment of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100 (8): 2807–2831.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Bel'tsevich D.G., Mel'nichenko G.A., Kuznetsov N.S. et al. Klinicheskie rekomendatsii Rossiyskoy assotsiatsii endokrinologov po differentsial'noy diagnostike intsidentalom nadpochechnikov. Endokrinnaya khirurgiya. 2016; 10 (4): 31–42 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Бельцевич Д.Г., Мельниченко Г.А., Кузнецов Н.С. и др. Клинические рекомендации Российской ассоциации эндокринологов по дифференциальной диагностике инциденталом надпочечников. Эндокринная хирургия. 2016; 10 (4): 31–42.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Manisha H. Shah, Whitney S. Goldner, Thorvardur R. Halfdanarson, et al. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, 2018. J Natl Compr Canc Netw. 2018; 16 (6): 693–702.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Fassnacht M., Arlt W., Bancos I. et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016; 175 (2): G1–G34.</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Bovio S., Cataldi A., Reimondo G. et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomo graphy series. J Endocrinol Invest. 2006; 29 (4): 298–302.</mixed-citation><mixed-citation xml:lang="ru">Bovio S., Cataldi A., Reimondo G. et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006; 29 (4): 298–302.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Gavras I. The incidentally discovered adrenal mass. N Engl J Med. 2007; 356 (19): 2005–2006.</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Eric Mirallié, Claire Blanchard, Cécile Caillard et al. Adrenocortical carcinoma: Impact of surgical treatment. Ann Endocrinol (Paris). 2019; 80 (5–6): 308–313.</mixed-citation><mixed-citation xml:lang="ru">Eric Mirallié, Claire Blanchard, Cécile Caillard, et al. Adrenocortical carcinoma: Impact of surgical treatment. Ann Endocrinol (Paris). 2019; 80 (5–6): 308–313.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Jung Min Lee, Mee Kyoung Kim, Seung Hyun Ko et al. Clinical Guidelines for the Management of Adrenal Incidentaloma. Endocrinol Metab (Seoul). 2017; 32 (2): 200–218.</mixed-citation><mixed-citation xml:lang="ru">Jung Min Lee, Mee Kyoung Kim, Seung Hyun Ko, et al. Clinical Guidelines for the Management of Adrenal Incidentaloma. Endocrinol Metab (Seoul). 2017; 32 (2): 200–218.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><mixed-citation>Papierska L., Ćwikła J., Rabijewski M. et al. Adrenal 131I-6β-iodomethylnorcholesterol scintigraphy in choosing the side for adrenalectomy in bilateral adrenal tumors with subclinical hypercortisolemia. Abdom Imaging 2015; 40: 2453–2460.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dong Wang, Zhi-Gang Ji, Han-Zhong Li, et al. Adrenalectomy was recommended for patients with subclinical Cushing's syndrome due to adrenal incidentaloma. Cancer Biomark. 2018; 21 (2): 367–372.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Valentina Morelli, Serena Palmieri. Adrenal incidentaloma: differential diagnosis and management strategies. Minerva Endocrinol. 2019; 44 (1): 4–18.</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Morelli V., Palmieri S. Adrenal incidentaloma: differential diagnosis and management strategies. Minerva Endocrinol. 2019; 44 (1); 4–18.</mixed-citation><mixed-citation xml:lang="ru">Morelli V., Palmieri S. Adrenal incidentaloma: differential diagnosis and management strategies. Minerva Endocrinol 2019; 44 (1): 4–18.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Mark Sherlock, Andrew Scarsbrook, Afroze Abbas. Adrenal Incidentaloma. Endocrine Reviews. 2020; 41 (6): 775–820.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Dylan S. Jason, Sarah C. Oltmann. Evaluation of an Adrenal Incidentaloma. Surg Clin North Am. 2019; 99 (4): 721–729.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Unger N. Adrenal incidentaloma: Diagnostic and therapeutic concept from an endocrinological perspective. Chirurg. 2019; 90 (1): 3–8.</mixed-citation></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Cyrańska-Chyrek E., Grzymisławska M., Ruchała M.. Diagnostic pitfalls of adrenal incidentaloma. Endokrynol Pol. 2017; 68 (3): 360–377.</mixed-citation><mixed-citation xml:lang="ru">Ewa Cyrańska-Chyrek, Małgorzata Grzymisławska, Marek Ruchała. Diagnostic pitfalls of adrenal incidentaloma. Endokrynol Pol. 2017; 68 (3): 360–377.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Bokhyan V.Yu., Pavlovskaya A.I., Gubina G.I., Stilidi I.S. Klinicheskaya otsenka gistologicheskikh sistem diagnostiki adrenokortikal'nykh opukholey. Arkhiv patologii. 2015; 77 (3): 17–22.</mixed-citation><mixed-citation xml:lang="ru">Бохян В.Ю., Павловская А.И., Губина Г.И., Стилиди И.С. Клиническая оценка гистологических систем диагностики адренокортикальных опухолей. Архив патологии. 2015; 77 (3): 17–22.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Korb T.A., Chernina V.Yu., Blokhin I.A. et al. Vizualizatsiya nadpochechnikov: v norme i pri patologii (obzor literatury). Problemy endokrinologii 2021; 67 (3): 26–36 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Корб Т.А., Чернина В.Ю., Блохин И.А. и др. Визуализация надпочечников: в норме и при патологии (обзор литературы). Проблемы эндокринологии 2021; 67 (3): 26–36.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
